PEPTOKING
EN

Heart and kidney

Outcomes beyond weight: heart attacks, strokes, heart failure and kidney disease.

4 peptides

  1. ApprovedDulaglutideGLP-1 receptor agonist (Fc fusion protein)31
  2. ApprovedLiraglutideGLP-1 receptor agonist31
  3. ApprovedSemaglutideGLP-1 receptor agonist31
  4. ApprovedTirzepatideDual GIP and GLP-1 receptor agonist39

Latest peptide news

All news
  1. Research

    REMODEL: primary kidney MRI outcomes show no significant difference versus placebo

  2. Research

    STEP UP exploratory analysis finds reduced liver fat with semaglutide

  3. Trial result

    Eloralintide with tirzepatide reduces weight in phase 2b trial

  4. Regulatory

    FDA says compounded GLP-1s with added vitamins are still copies of approved drugs

  5. Safety

    TGA finds undeclared semaglutide in counterfeit retatrutide after hospitalization

  6. Regulatory

    WADA keeps GLP-1 drugs off its 2027 Prohibited List and continues monitoring

  7. Research

    ESC heart failure guidelines back semaglutide or tirzepatide in HFpEF with obesity

  8. Approval

    FDA approves Mounjaro to lower heart attack, stroke and CV death risk in type 2 diabetes